The global digital breast tomosynthesis equipment market size was worth USD 1736.62 million in 2024. This value is projected to grow at a CAGR of 14.14% and will be worth USD 3364.29 Million by 2029.
DBT is a medical 3D breast imaging technique that is a full-fledged digital mammography system where an X-ray tube rotates round to capture breast images from all angles with low radiation dosage and gathered together to view on the monitor.
The growing incidence of breast cancer across the globe is the key factor driving the DBT Equipment market growth. According to National Breast Cancer Foundation, an estimated 268,600 with invasive breast cancer and 62,930 women with non-invasive (in situ) breast cancer were diagnosed in the United States in 2019. The death expectancy was estimated in 41,760 women. It is also projected 1 in 8 women in the United States develop breast cancer in their lifetime. Across the world, the North American region is estimated to witness huge demand for this DBT equipment due to the significant growth of breast cancer occurrence in this region.
Growing awareness among people towards 2D & 3D mammography, well-developed equipment for the treatment, and technological advancements in the techniques for the quick diagnosis and detection of breast lesions is further accelerating the market growth. Escalating expenditure on healthcare and rising awareness about the benefits associated with DBT across the world are also contributing to a significant boost to the global digital breast tomosynthesis market growth.
The rising cost of breast cancer treatment & maintenance of installed technology hampers the digital breast tomosynthesis equipment market growth. Skilled experts or trained lab technicians/radiologists are required to use the equipment. The shortage of this skilled human resource is expected to impact the growth of the digital breast tomosynthesis equipment market to some level. Shortages of reimbursement policies from the government and non-government bodies and lack of complete knowledge regarding digital breast tomosynthesis in a few countries are further expected to obstruct the market growth.
The emergence of the global pandemic has affected the market in many aspects, such as the decline in revenue, production, and distribution. The rapid surge of the covid-19 has led to the nationwide lockdown. Due to strict lockdown and closure of commercial businesses in almost every part of the world, the covid-19 pandemic disrupted the supply chain. It brought many large and small businesses to a halt. Due to a lack of staff and travel bans, the Digital Breast Tomosynthesis (DBT) Equipment industry has experienced a substantial adverse effect on supply chains, demand, and production. However, with the manufacture and distribution of vaccines, the lifting of lockdowns, and the lifting of travel bans, the world is expected to return to normal gradually. Other significant factors that could significantly affect the industry's development include government policies to help the economy recover from the recession and increase the number of start-ups in the Digital Breast Tomosynthesis (DBT) Equipment sector. As a result, the study seeks to illustrate the approaches and tactics for developing and maintaining business growth by applying new techniques.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Product, End-User, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
Market Leaders Profiled |
Hologic Inc., Siemens Healthineers, Fujifilm Corporation, G.E. Healthcare, Internazionale Medico Scientifica S.r.l, and Planmed Oy. |
Based on product type, the DBT equipment segment is presently leading the market with the most significant shares and is predicted to continue its dominance throughout the forecast period. The growth of this segment is majorly attributed to a moderate increase in breast cancer throughout the world. Having sound knowledge related to digital breast tomosynthesis is boosting the market. The market growth is also due to the advantages offered by the new products launched.
The 3D up-gradation segment is estimated to have a quick growth rate during the forecast period due to the rising awareness among women related to the digital equipment being used to boost the market growth.
Based on End User, the Hospitals captured a large market share. Its growth rate is projected to be nearly 15% for the forecast period.
Based on the End-User, the hospital's segment accounts for the highest revenue share and is projected to see significant growth in Indian hospitals during the forecast period. This segment is likely to extend with a CAGR of 14.9%, and the increase is due to the extensive records of women with breast cancer and other health problems related to the breast in the hospitals, boosting the market growth.
The diagnostic centers segment is estimated to have the quickest growth rate during the period. The increasing number of diagnostic centers globally is considered to accelerate the segment market growth.
IN 2023, the North American market dominated the global DBT equipment market and was estimated to retain its leading position throughout the forecast period. During the forecast period, the United States dbt equipment market is expected to showcase domination in the North American market. The Canadian market is estimated to register a healthy growth rate. North American countries such as the United States and Canada have a high prevalence of breast cancer, which is estimated to provide immense market growth. Notably, the U.S. has the highest share in North America. This region has a 55.1% share in terms of value. The increase is due to the colossal occurrence of breast cancer and also better healthcare infrastructure provided.
Europe is very close to North America and was the second-largest regional market in 2023. The U.K. is predicted to lead the European market due to technological advancements. Also, increasing awareness among women regarding the DBT and its early diagnosis is one factor propelling the U.K. dbt equipment market growth.
The Asia Pacific is the fastest-growing regional market and is the most lucrative region for DBT Equipment Market. Within the Asia Pacific, China accounted for the largest market share in this market.
Latin America size was expected to reach a value of USD 273.18 million by 2029. This region is observed to have sluggish growth steadily throughout the period and also less market perception. In this region, the hospital's segment is accounted to have a growth rate of 15% along the period.
MEA is another region to have inclined growth during the forecast period. This region size is expected to have a value of USD 165.52 billion by 2029, with a CAGR value of 11.6%. The growth in this region is due to low acceptable government policies and is likely to have less penetration market.
Some notable companies operating the global digital breast tomosynthesis (DBT) equipment market profiled in the report are Hologic Inc., Siemens Healthineers, Fujifilm Corporation, G.E. Healthcare, Internazionale Medico Scientifica S.r.l, and Planmed Oy.
On January 24, 2020, Fujifilm Corporation introduced its new mammography imaging technique with the advanced technologies for Aspire Cristalle, a digital breast tomosynthesis that includes S-view.
On November 12, 2019, Hologic Inc. received approval from the FDA for its 3DQuorum Imaging Technology which was powered by Genius A.I. This technology works in deuce with high clarity H.D. high-resolution imaging technology that decreases the tomosynthesis image level for radiologists by 66%.
On July 24, 2013, G.E. Healthcare received a CE mark to approve SenoClaire tomosynthesis with 3D capacity. This device uses constant restoration of data collected from the images taken when screening or examining the breast is performed from different angles. Also, the system lowers the dosage used for analysis which helps in detecting breast cancer.
On March 24, 2017, the Senographe Pristina system, a three-dimensional digital breast tomosynthesis system developed, was launched by G.E. Healthcare. Senographe Pristina has a feature that can handheld remote control called Pristina Dueta. Technology enhances the visualization of breast lesions with lower X-ray doses.
By Product
3-D Upgradation
DBT Equipment
By End User
Hospitals
Diagnostic centers
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region